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ABSTRACT: Background: Striatal dopamine deficiency
and metabolic changes are well-known phenomena in
dementia with Lewy bodies and can be quantified in vivo
by 123I-Ioflupane brain single-photon emission computed
tomography of dopamine transporter and 18F-fluorodesoxy-
glucose PET. However, the linkage between both bio-
markers is ill-understood.
Objective: We used the hitherto largest study cohort of
combined imaging from the European consortium to elu-
cidate the role of both biomarkers in the pathophysiologi-
cal course of dementia with Lewy bodies.
Methods: We compared striatal dopamine deficiency
and glucose metabolism of 84 dementia with Lewy
body patients and comparable healthy controls. After
normalization of data, we tested their correlation
by region-of-interest–based and voxel-based methods,
controlled for study center, age, sex, education,
and current cognitive impairment. Metabolic connectivity
was analyzed by inter-region coefficients stratified by
dopamine deficiency and compared to healthy controls.
Results: There was an inverse relationship between
striatal dopamine availability and relative glucose
hypermetabolism, pronounced in the basal ganglia and
in limbic regions. With increasing dopamine deficiency,
metabolic connectivity showed strong deteriorations
in distinct brain regions implicated in disease symp-
toms, with greatest disruptions in the basal ganglia and
limbic system, coincident with the pattern of relative
hypermetabolism.
Conclusions: Relative glucose hypermetabolism and
disturbed metabolic connectivity of limbic and basal
ganglia circuits are metabolic correlates of dopamine
deficiency in dementia with Lewy bodies. Identification
of specific metabolic network alterations in patients
with early dopamine deficiency may serve as an addi-
tional supporting biomarker for timely diagnosis of
dementia with Lewy bodies. © 2019 The Authors.
Movement Disorders published by Wiley Periodicals,
Inc. on behalf of International Parkinson and Movement
Disorder Society.
Key Words: dopamine deficiency; glucose metabolism;
Lewy body dementia; metabolic connectivity; PET
imaging
Dementia with Lewy bodies (DLB) is the second-most
common type of late-onset degenerative dementia,1,2
which is characterized clinically by its core symptoms: fluc-
tuations in cognition and alertness, parkinsonism, visual
hallucinations, and rapid eye movement (REM) sleep
behavior disorder. According to the accepted diagnostic
criteria, DLB should be suspected when onset dementia
occurs before or concurrently with parkinsonism.3,4 The
complex clinical picture of DLB renders its diagnosis chal-
lenging, especially at an early disease stage.3,5 For this rea-
son, molecular biomarkers, in particular dopamine
transporter imaging by 123I-Ioflupane brain single-photon
emission computed tomography (DaT-SPECT) and 18F-
fluordeoxyglucose brain PET (FDG-PET), are now
accepted tools supporting a diagnosis of DLB.3,6,7
Nigrostriatal degeneration, as indicated by reduced
striatal DaT-SPECT binding, can distinguish DLB at an
early disease stage from other neurodegenerative condi-
tions, especially Alzheimer’s disease (AD).8,9 A previous
study showed that reduced DaT-SPECT binding in the
posterior putamen provides highly sensitive differential
diagnosis of DLB.10 An incomplete nigrostriatal
dopaminergic degeneration is detectable by DaT-
SPECT, even though parkinsonian motor symptoms are
not yet conspicuous to clinical examination.3,11
FDG-PET provides a surrogate measure of neuronal
injury, which can support a diagnosis of DLB by reveal-
ing region-specific patterns of altered glucose metabo-
lism.3,12 Our consortium recently investigated metabolic
patterns and their covariance with clinical core features
in the hitherto largest cohort of DLB patients undergoing
molecular imaging, in a study within the framework of
the European DLB (E-DLB) Consortium.5.Extending
beyond regional changes in metabolism, network analy-
sis of FDG-PET revealed altered patterns of metabolic
connectivity between different brain regions.13 One such
FDG-PET study in DLB patients showed patterns of
perturbed metabolic connectivity involving cholinergic
and dopaminergic pathways and in association with the
spreading synucleinopathy occurring in DLB.14 How-
ever, studies using functional MRI (fMRI) have provided
inconsistent evidence for increasing, decreasing, or
unaltered functional connectivity in different brain
regions or functionally related neuronal circuits in DLB
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patients compared to healthy controls (HCs) and/or AD
patients.15-19
Although both DaT-SPECT and FDG-PET are now
well-established procedures for indicative or supportive
diagnosis of DLB, there is only limited documentation
of the covariance of the two biomarkers. In Parkinson’s
disease (PD) and atypical parkinsonian syndromes, met-
abolic network expression and dopamine availability
were found to provide complementary information
underlying the disease process.20,21 Although there are
several studies investigating the relationships of these
two biomarkers’ relationship in PD,21,22 corresponding
results are available in only in a few DLB cases so
far.20,23 Therefore, we undertook to evaluate the rela-
tionship between individual dopamine deficiency and
altered glucose metabolism in a well-powered, cross-
sectional analysis of our large multicenter E-DLB
cohort. First, we correlated individual dopamine defi-
ciency as indicated by DaT-SPECT with striatal glucose
metabolism measured by FDG-PET. We then under-
took regional and voxel-wise analyses to investigate the
association between the two biomarkers throughout the
brain. Finally, we calculated metabolic connectivity as a
function of the extent of dopamine deficiency.
Materials and Methods
Research Project, Conception, Design, and
Patient Selection
We took advantage of the framework of the E-DLB
consortium that had agreed to share clinical and imaging
data from patients with DLB,24 including recently publi-
shed findings of the project’s FDG-PET arm.25 From the
189 patients with an available anonymized brain FDG-
PET scan from nine centers, we assembled the 89 patients
with additional DaT-SPECT images in their original
Digital Imaging and Communications in Medicine
(DICOM) format. Five patients were excluded because of
insufficient demographic data (see a previous work25),
resulting in 84 included subjects. Age-matched DaT-
SPECT images of 37 historical HCs from a previously
published, multicenter study26 and FDG-PET images of
28 HCs imaged in Genova and Munich (14 each) served
as control material.
Local institutional ethics committee approvals for the
retrospective analyses were available for all centers,
including the transfer of imaging data. Patients gave
informed written consent for the imaging procedure
and radiopharmaceutical application.
DaT-SPECT and FDG-PET Procedure and
Preprocessing
We compiled the DaT-SPECT DICOM files and eval-
uated them with Hermes HybridBRASS using the stan-
dard settings for this analysis. Correction for age was
included in the generation of Z-score values against the
corresponding HC data. We calculated the DaT ratio in
the bilateral putaminal volumes of interest (VOIs) as
defined in BRASS model 5, relative to uptake in the
bilateral occipital lobe reference region.
FDG-PET preprocessing for all subjects was performed
in Munich according to procedures established in the pre-
vious E-DLB work.25 In brief, the original FDG-PET
DICOM image files were spatially normalized (nonlinear
warping; transient input filter 8 mm3; 16 iterations; fre-
quency cutoff 3; regularization 1.0; no thresholding) with
PMOD (V3.5; PMOD Technologies, Basel, Switzerland)
to an FDG-PET template. Individual images were inten-
sity normalized to their global mean and then smoothed
using a Gaussian filter (8 mm3) to obtain maps of FDG
uptake as standardized uptake value ratios (SUVrs) in
77 predefined cortical and subcortical gray matter VOIs
of the Hammers atlas27 after exclusion of the ventricular
system and the corpus callosum. Brain regions other than
insula, cerebellum, and pons were assigned to one of the
following six structural or functional compartments:
frontal cortex, parietal cortex, temporal cortex, occipital
cortex, limbic system, and basal ganglia. The putamen
uptake represented the extended striatum, given that VOI
placement in the caudate nucleus tended to impinge upon
the cerebral ventricles.
To evaluate potential quantification bias of relative
glucose metabolism increases arising from the normali-
zation method, we also reprocessed all data by scaling
to cerebellar gray matter values and a cluster-based
normalization. Corresponding results are presented
online (see Supporting Information Fig. 1). The refer-
ence cluster was determined by similarity analysis
(voxels ≤2% deviation) between DLB patients and
HCs.28 Values deriving from global mean scaling were
used for further analyses. Data were visually checked
for image quality after each process step. The mean
time interval between FDG-PET and DaT-SPECT imag-
ing was +3.0  4.8 months. Disease duration was the
elapsed time between the first symptoms of the patients
and the date of scanning.
Statistical Analysis
Statistical tests were performed using SPSS (V25.0;
IBM Corp., Chicago, IL) and statistical parametric
mapping (SPM; V12; Functional Imaging Laboratory,
The Wellcome Trust Centre in the Institute of Neurol-
ogy, University College of London, London, UK) run-
ning in Matlab (version R2016a; The MathWorks,
Inc., Natick, MA). We tested normality of data distri-
bution for DaT ratios and all regional FDG-PET SUVr
measurements with the Kolmogorov-Smirnov test. Puta-
men DaT ratios and regional FDG-PET SUVrs in the
putamen were compared between the DLB patient and
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FIG. 1. VOI and voxel-based associations of DaT availability and relative glucose metabolism. (A) Put_L/R, left/right putamen. (B) FDG SUVr, relative
glucose metabolism. (C) Different symbols indicate different centers. (D) Clusters of negative/positive (red/ blue) associations (predictor DaT availability,
outcome variable and relative glucose metabolism). (E) Clusters of relative hypo-/hypermetabolism (blue/red; DLB vs. HC). (F) Quantitative comparison
of associations between DaT availability and relative glucose metabolism (black bars) and the disease-related pattern of DLB patients when compared
to HCs (white bars) for different brain regions. The average values (SD [standard deviation]) of regional T-scores deriving from SPM are given for each
brain region. *P < 0.05; **P < 0.01, error bars indicate SDs. Brain regions in D/E are masked by a gray matter atlas. [Color figure can be viewed at
wileyonlinelibrary.com]
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HC groups by an unpaired Student’s t test. A signifi-
cance level of P < 0.05 was applied in all analyses.
Correlation Analyses
Pearson’s coefficient of correlation (R) for the two
biomarkers in the putamen was calculated after
adjusting for center, subject age, sex, education level,
and disease duration. A subgroup of 70 DLB patients
also allowed correction for current cognitive impair-
ment as assessed by the Mini-Mental State Examination
(MMSE) score. Associations between each subject’s
DaT Z-score and FDG-PET SUVr in all predefined
brain regions were characterized by applying linear
regression analyses. All values were adjusted for age
(n = 84), sex (n = 84), education (n = 84), disease dura-
tion (n = 84), and MMSE (n = 70) by linear regression
before the analysis. We applied a strict Bonferroni cor-
rection to account for multiple comparisons of the
77 brain regions.
Voxel-wise Analyses
Voxel-wise statistical analyses were performed using
SPM12. A regression analysis was performed using
putamen DaT Z-Scores as predictor and voxel-wise
FDG-PET SUVr as outcome variable, with imaging cen-
ter, subject age, sex, and education level as covariates
(SPM threshold P < 0.05, uncorrected [unc.]). Addition-
ally, we made a voxel-wise contrast of FDG-PET SUVr
images of DLB patients versus HCs using an unpaired
t test and compared regional t-scores between the
regression analysis and the contrast against HCs (SPM
threshold P < 0.005, unc.). Binarized SPM maps were
tested for similarity by calculation of Dice coefficients
as previously described.29
Metabolic Connectivity
We assessed metabolic connectivity from inter-regional
coefficients of FDG-PET SUVr for DLB patients at differ-
ent stages of dopamine deficiency and for the HC group,
as initially described by Horwitz and colleagues.30 For
this purpose, regional FDG-PET values of all 77 brain
regions were extracted after normalization to global
mean, and an inter-region correlation matrix of 77 × 77
Pearson’s correlation coefficients was created for each
analyzed group.
The DLB cohort was stratified by tertiles of 28 subjects
each with severe, intermediate, and mild dopamine defi-
ciency to the DaT-SPECTZ-Score (age/sex not statistically
different). Thus, we performed the connectivity analysis in
these three subgroups and a group of 28 age-matched
HCs to avoid statistical biases attributed to differing sam-
ple sizes. Single inter-region coefficients of different brain
areas were compared between the resulting four groups by
analysis of variance, including Bonferroni correction for
the number of coefficients studied and the number of
subgroups. Fisher’s R to Z transformation was performed
for all values to enhance normal distribution. A signifi-
cance level of P < 0.05 after Bonferroni correction was
applied in all analyses. Furthermore, the regional regres-
sion coefficients between DaT Z-Score and FDG-PET
SUVr in putamen were correlated with mean loss of con-
nectivity in the corresponding investigated brain regions
defined as the difference (delta) between DLB and HCs,
calculated by subtracting values of each inter-region
coefficient.
Results
Associations Between Dopamine Deficiency
and Relative FDG Uptake
Demographics and disease parameters of the DLB
cohort and our historical HC groups are presented in
Table 1. Our DLB cohort revealed a strongly reduced
dopamine transporter availability in bilateral putamen
(–48%, P < 0.001, t test; Fig. 1A) and significantly higher
relative glucosemetabolism rates (+7.5%,P < 0.001, t test;
Fig. 1B) in the bilateral putamen when compared to the
age-matched HC group. Importantly, there was a negative
association between DaT Z-scores and FDG-PET SUVr in
the putamen after controlling for imaging center, subject
age, sex, and education (R = –0.269; P = 0.016, partial
correlation; Fig. 1C). The two imaging biomarkers were
still significantly associated after additional controlling
for disease duration (R = –0.253; P = 0.030, partial
correlation). Furthermore, this association remained
stable in the 70 cases where MMSE score was available
to control for current cognitive impairment, together
with the usual adjustment for age, sex, and education
(R = –0.318; P = 0.009, partial correlation), compared
to only adjusting for age, sex, and education in that sub-
group (R = –0.322; P = 0.008, partial correlation). We
TABLE 1. Demographics and composition of the study
collective
DLB
HC
(FDG-PET)
HC
(DaT-SPECT)
N 84 28 37
Age (y) 72.6  7.0 73.2  7.6 70.1  6.0
Sex (♂/♀) 47♂ 37♀ 17♂ 11♀ 21♂ 16♀
MMSE (0–30) 22.6  4.3
Education (y) 12.1  3.7
Disease duration (y) 2.7  2.0
Parkinsonism 82%
Visual hallucinations 65%
Fluctuating cognition 73%
REM sleep behavior
disorder
49%
Possible DLBa 26%
Probable DLBa 74%
aMcKeith criteria of 2017.3
N, number of subjects; y, years.
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could not control for study center in combination with
MMSE because of the heterogeneous MMSE distribu-
tion across study centers.
Compared to HCs, the DLB-related pattern (DLBRP)
in FDG-PET showed a relatively reduced metabolism in
the parietal, occipital, and, to a lesser extent, frontal
cortices and a relative hypermetabolism in the basal
ganglia, parts of the limbic system, the motor cortices,
and the cerebellum (Fig. 1E).
The voxel-wise regression analysis revealed clusters
showing a negative correlation between both bio-
markers, which was most conspicuous in the basal
ganglia and limbic system, that is, the putamen, thala-
mus, SN, and anterior and posterior cingulate gyrus
(Fig. 1D, red). Clusters with positive associations
were observed in parietal and occipital cortices as well
as in the cerebellum (Fig. 1D, blue). Negative correla-
tion clusters in the basal ganglia and limbic system
overlapped with regions of general increases within
the DLBRP (Dice similarity: 24%; Fig. 1E,F). The
positive correlation clusters in the occipital cortex
overlapped with regions of generally reduced relative
glucose metabolism within the DLBRP (Dice similar-
ity: 41%; Fig. 1E,F). Relative FDG uptake in the pari-
etal cortex showed only a weak positive correlation
with dopamine deficiency, but this cortical region rev-
ealed the strongest decrease of relative glucose metab-
olism within the DLBRP (Fig. 1F). Relative increases
of glucose metabolism in temporal regions were
accompanied by weak correlations with nigrostriatal
dopamine degeneration (Fig. 1F). There were only
minor overlaps between negative correlation clusters
and reduced relative glucose metabolism in DLB (Dice
similarity: 3%) and between positive correlation clus-
ters and increased relative glucose metabolism in DLB
(Dice similarity: 8%).
Next, we applied region-based linear regression of
FDG uptake as a function of DaT Z-Scores for all
77 brain regions with correction for multiple compari-
sons (Fig. 2) after adjustment for age, sex, education,
disease duration, and current cognitive function. Nota-
bly, only negative significant associations were
observed: in the right nucleus accumbens (R = –0.380;
F2,81 = 13.9; P = 0.028), the right thalamus (R = –
0.510; F2,81 = 28.9; P = 0.0001), the bilateral anterior
cingulate gyrus (R = –0.402/–0.389; F2,81 = 15.8/14.6;
P = 0.012/0.020), the right posterior cingulate gyrus
(R = –0.389; F2,81 = 14.6; P = 0.020), and the right sub-
callosal area (R = –0.367; F2,81 = 12.8; P = 0.046;
Fig. 2). The other brain regions did not show significant
correlations. The initially observed direct association in
the putamen did not survive correction for multiple
comparisons (Fig. 2).
Metabolic Connectivity at Different Stages of
Dopamine Deficiency in DLB
Metabolic connectivity was analyzed in three sub-
groups of DLB patients of the same size (28 subjects
each) stratified according to their degree of dopamine
FIG. 2. Region-based associations of dopamine transporter availability and relative glucose metabolism. The range of FDG-SUVr values of healthy controls
standard deviation indicated in gray. Significant associations (after Bonferroni correction) of 6 of 77 tested regions are indicated with an asterisk (“*”).DaT,
putaminal dopamine transporter. R, right. L, left. FDG-SUVr, relative glucosemetabolism. [Color figure can be viewed at wileyonlinelibrary.com]
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deficiency (mild, mean DaT Z-Score of –1.6  0.9;
intermediate, mean DaT Z-Score of –3.5  0.3; severe,
mean DaT Z-Score of –4.5  0.5) and compared to
that in a size- and age-matched HC group (28 subjects)
with presumably intact nigrostriatal dopamine innerva-
tion (Fig. 3A–D).
FIG. 3. Metabolic connectivity at different stages of dopaminergic loss, as indexed by DaT SPECT. (A–D) Single boxes indicate inter-regional
Z’. Regions with significant differences between groups are highlighted with black, black-dotted, and white lines. (E–I) DD = dopamine depletion
to DaT SPECT. Error bars indicate standard deviations. FRO, frontal cortex; TMP, temporal cortex; PAR, parietal cortex; OCC, occipital
cortex; I, insula; BAG, basal ganglia; C, cerebellum and brainstem; LIM, limbic structures. [Color figure can be viewed at wileyonlinelibrary.com]
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Strikingly, the strongest alterations of metabolic
connectivity in comparison to HCs were observed
within the limbic circuits and basal ganglia (see black
boxes in Fig. 3A–D and 3E,F) and between the limbic
circuit and basal ganglia (see black dotted boxes in
Fig. 3A–D and 3G). The metabolic connectivity was
increased in the DLB group with mild dopamine defi-
ciency compared to age-matched HCs, but connectiv-
ity then fell significantly lower for DLB stages of
intermediate or severe dopamine deficiency (Fig. 3E–G).
We also observed a significant decrease of metabolic
connectivity between parieto-occipital brain areas and
the limbic system/basal ganglia, which was enhanced
with increasing dopamine deficiency (see white boxes
in Fig. 3A–D and 3H,I). Other brain areas showed no
significant differences in metabolic connectivity.
Metabolic connectivity was significantly lower for
regions with a higher association between dopamine
deficiency and relative glucose metabolism (R = –0.665;
P < 0.01; Fig. 4). Single regions clustered along their
defined anatomical or functional compartments when
plotting regression coefficients deriving from the associ-
ation between dopamine deficiency and relative glucose
metabolism together with connectivity changes. In sum-
mary, we observed a clear linkage between the relative
hypermetabolism associated with dopaminergic loss
and decreased metabolic connectivity at the regional
level of DLB patients.
Discussion
We present the first large-scale investigation of the rela-
tionship between dopamine deficiency in the bilateral
putamen and global perturbations of relative glucose
metabolism in DLB patients. Our data provide evidence
for an association between dopaminergic deficiency and
increased relative glucose metabolism pronounced in the
basal ganglia and limbic system, independent of disease
duration, current cognitive impairment, and other com-
mon covariates. Metabolic connectivity in these same
brain areas increases slightly at an early stage of dopamine
deficiency, but deteriorates strongly when nigrostriatal
degeneration is of intermediate or severemagnitude.
An extensive body of research documents the PD-related
pattern (PDRP) of metabolism in relation to clinical
and dopaminergic measures.20,21 There was a significant
inverse relationship between dopamine transporter avail-
ability in the striatum and PDRP expression, whereas nei-
ther extent of dopamine deficiency nor PDRP expression
correlated strongly with disease duration or severity.20 In
our DLB cohort, region-based and voxel-wise correlation
analyses also showed strong associations between dopa-
mine deficiency and the disease-specific metabolic pattern
of DLB. Notably, we found a significant correlation
between dopamine deficiency in the putamen and increas-
ing relative glucose metabolism throughout the bilateral
striatum, resulting in an overall striatal hypermetabolism
of DLB subjects compared to HCs. Until now, changes of
striatal glucose metabolism have not been evaluated in
detail with respect to the course of DLB, although the stri-
atum is certainly vulnerable to DLB pathology.8 In PD, it
has been shown that the neuronal firing rate and syn-
chrony of neurons in the dorsal striatum is altered along
the course of disease progression, in concert with continu-
ing dopamine deficiency.31 This relationship may arise
because of effects of a pacemaker center in the basal gang-
lia that compensates dopaminergic loss with increased
neuronal firing and consequently increased metabolic
activity.32 Thus, our current findings in DLB could also
reflect a compensatory or disinhibition mechanism
whereby metabolism increases in the partially dopamine-
depleted striatum. Importantly, the association between
loss of dopamine innervation and relatively increasing glu-
cose metabolism in the putamen remained after control-
ling for disease duration and current cognitive function, as
indexed by theMMSE score.
Compared to the PDRP, the DLBRP measured in our
study showed additional regions of relative hypometabolism
in the occipital cortices and, even more important, addi-
tional regions of relative hypermetabolism in the limbic sys-
tem. In comparison to PD, patients with DLB present with
additional core symptoms like visual hallucinations and cog-
nitive impairment arising from the more pronounced
FIG. 4. Association between relative regional hypermetabolism and loss of
connectivity. DaT, putaminal dopamine transporter. Regression coefficient
(association analysis of DaT availability and relative glucose metabolism;
Fig. 2). Change of metabolic connectivity (Δ mean Z’ vs. healthy controls;
Fig. 3). [Color figure can be viewed at wileyonlinelibrary.com]
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cortical involvement. As we have observed, additional brain
regions, such as the limbic system, also showed relative glu-
cose hypermetabolism in the contrast between DLB patients
andHCs and, furthermore, revealed a strong negative corre-
lation with the extent of dopaminergic loss in the putamen
(Fig. 1F).We speculate that increasing relative limbic glucose
metabolism arises secondary to impaired dopaminergic sig-
naling in the basal ganglia, perhaps attributable to disinhibi-
tion or as a compensatory response to decreasing signal
input. This finding is of particular interest given that it may
also harbor the molecular basis for the cingulate island sign
in DLB, that is, the relative sparing of mid-posterior cingu-
late cortex metabolism.33 Some areas with a negative corre-
lation between putaminal DaT-SPECT and voxel-wise
FDG-PET were observed in the white matter and near the
ventricles. This probably spurious finding could be related
to the presence of greater AD-like and vascular pathology in
those DLB subjects with relatively preserved dopaminergic
innervation, resulting in proportionately greater atrophy
and white matter disease. Future imaging studies need to
draw attention toward the impact of various existing
copathologies in DLB on our observed association between
dopaminergic loss in striatum and metabolic function in the
brain.
To get a deeper insight into potential pathomechanisms
resulting in perturbed glucose metabolism in DLB sub-
jects, we investigated metabolic connectivity in FDG-PET
by inter-region coefficient methods. Functional connectiv-
ity in DLB subjects has already been investigated in several
fMRI studies.15-19Most of these fMRI studies investigated
the discrepancies between DLB subjects and HC and/or
AD subjects, while focusing on particular brain regions
known to be affected in the respective diseases. As we have
demonstrated in the present study, some of the discrepant
findings of those fMRI studies may arise from reporting
connectivity alterations without adjustment for the stage
of dopaminergic loss of the included DLB subjects. In
our cohort, the combined analysis of dopamine deficiency
and relative glucose metabolism offers the opportunity
to investigate metabolic connectivity as a function of
dopaminergic loss. Stratified as mild/intermediate/severe
dopamine degeneration, we found seemingly increased
metabolic connectivity in limbic and basal ganglia regions
at the early stage of dopaminergic loss compared to that
in HCs (Fig. 3). Enhanced metabolic connectivity has
already been reported between the right posterior cingu-
late cortex and other brain regions (inter alia the limbic
system) in a previous study of DLB subjects.16 With
increasing nigrostriatal dopamine degeneration, the meta-
bolic connections involving the basal ganglia and limbic
system decreased and the metabolic connectivity of those
brain regions was significantly lower than for DLB sub-
jects withmild dopamine innervation loss in the putamen.
This finding supports the conjecture that relative
hypermetabolism in the basal ganglia and limbic system
in early DLB disease stages represents a disinhibition or
compensatory mechanism, whereas impaired metabolic
connectivity at later disease stages could reflect a break-
down or decompensation of the increasingly disturbed
neuronal activity. Our findings are supported by one
fMRI investigation, which found decreased functional
connectivity in limbic and basal ganglia clusters of tem-
poral and frontoparietal networks of a group of
patients with advanced DLB.17 An analogous compen-
satory recruitment hypothesis has already been pro-
posed to occur in the course of AD.34 In this scenario,
connectivity initially increases because new brain areas
are recruited, and impaired regions become hyperactive
to compensate for functional loss in a process pre-
senting as relative hypermetabolism to FDG-PET. The
compensation process cannot be maintained when neu-
rodegeneration proceeds past some point, whereupon
decreasing metabolic connectivity is declared at this
later disease stage. The seemingly dynamic changes of
metabolic connectivity involving the limbic system
might explain why relative FDG uptake did only partly
differ in the voxel-wise analysis for the entire DLB
group as compared to HCs (see Fig. 1).
Among the limitations of the study, we note that
DLB diagnoses were obtained in different clinical set-
tings and without histopathological verification. Fur-
thermore, there might occur some selection bias into
the direction of a more complex cohort of DLB patients
in comparison to the general average in populations,
given that patients evaluated by both imaging bio-
markers had potentially a more conflicting clinical
examination. Potential confounders, such as different
cameras or nonstandardized enrollment of patients
(clinical evaluation and examination), were minimized
by inclusion of the imaging center as a covariate. Filter-
ing of FDG-PET data was used to correct for possible
spatial mismatch between subjects. Nonetheless, we
cannot fully exclude the possibility of some remaining
effects attributed to the multicenter design of this cross-
sectional study.
The use of a global mean normalization may raise con-
cerns about a potential artificial relative hypermetabolism
attributed to a lower global glucosemetabolism in subjects
affected by DLB (i.e., causing a low denominator).35,36
Although some research indicates absolute declines in cor-
tical glucose consumption in patients with PD,37 others
report no significant difference between global glucose
metabolism in PD patients compared to HCs, despite a
focal increase of striatal metabolism.38Moreover, another
study found a correlation between the changes of glucose
metabolism in subcortical brain regions and motor func-
tion deterioration, which speaks against the interpretation
that increased values aremerely artefacts of the normaliza-
tion process.39 To strengthen this argument, we tested for
the robustness of our findings of increased striatal glucose
metabolism with normalization to other reference regions
(see Supporting Information Fig. 1). Although there were
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varying degrees of relative increase in the striatum, corre-
lations of relative glucose metabolism with reduced DaT
availability in the putamen remained stable. Thus, some
areas with relatively increased glucose metabolism, such
as the white matter of the bilateral frontal and parietal cor-
tices, which might have been artifacts of the global mean
normalization, did not significantly influence the present
key results.
Our inter-region coefficient method represents a simpli-
fied model to assess metabolic or functional connectivity,
which has previously revealed inter-regional correlations
in an fMRI study.40 However, our primary focus was to
search for differences in metabolic connectivity as a func-
tion of the stage of putaminal dopaminergic loss in DLB.
Therefore, we argue that a simple model is well suited to
the task at hand. We note that FDG-PET has inherently
lower spatial resolution compared to fMRI studies, but
presume that functional connectivity operates for anatom-
ical regions of the scale of our 77 atlas-based brain regions.
FDG-PET has shown comprehensible results regarding
the sufficient spatial resolution for metabolic connectivity
analyses in AD subjects.41 We note that the MMSE score
certainly does not represent all aspects of disease severity
in DLB. Unfortunately, to our knowledge, there is no
widely accepted score to measure overall clinical severity
in DLB. Therefore, MMSE was the only feasible, stan-
dardized index for use in this multicenter study.
Overall, we present the, so far, largest combined anal-
ysis of dopamine deficiency to DaT-SPECT imaging and
widespread cerebrometabolic changes to FDG-PET in
the same DLB subjects. Our data indicate a strong inter-
relation, with a pronounced association of dopamine
deficiency with increasing relative glucose metabolism in
the basal ganglia and limbic system. Furthermore, a
more advanced stage of dopaminergic loss manifested in
decreased metabolic connectivity within brain regions of
the disease-related metabolic pattern of DLB, pro-
nounced in the basal ganglia and limbic system. These
findings clearly show that disturbed brain metabolism in
particular regions is linked to extent of dopaminergic
loss in DLB. As already proposed for PD and other atyp-
ical parkinsonian syndromes, the identification of meta-
bolic network alterations at early stages of dopaminergic
loss, preceding onset of motor symptoms, may serve as a
supporting biomarker for diagnosis of DLB.
Acknowledgments: We are grateful to the European Dementia with
Lewy Bodies consortium for this inspiring collaboration and intellectual
exchange. We thank radiographers and technicians at all study centers for
their invaluable support in data acquisition.
References
1. Barker WW, Luis CA, Kashuba A, et al. Relative frequencies of
Alzheimer disease, Lewy body, vascular and frontotemporal demen-
tia, and hippocampal sclerosis in the State of Florida Brain Bank.
Alzheimer Dis Assoc Disord 2002;16:203–212.
2. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias.
Lancet 2015;386:1683–1697.
3. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and manage-
ment of dementia with Lewy bodies: fourth consensus report of the
DLB Consortium. Neurology 2017;89:88–100.
4. Walker Z, Moreno E, Thomas A, et al. Evolution of clinical features
in possible DLB depending on FP-CIT SPECT result. Neurology
2016;87:1045–1051.
5. Morbelli S, Chincarini A, Brendel M, et al. Metabolic patterns
across core features in dementia with lewy bodies. Ann Neurol
2019;85:715–725.
6. Bauckneht M, Arnaldi D, Nobili F, Aarsland D, Morbelli S. New
tracers and new perspectives for molecular imaging in Lewy body
diseases. Curr Med Chem 2018;25:3105–3130.
7. McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of
dopamine transporter imaging with 123I-FP-CIT SPECT in dementia
with Lewy bodies: a phase III, multicentre study. Lancet Neurol
2007;6:305–313.
8. Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson
disease with dementia and dementia with Lewy bodies? Acta Neuro-
pathol 2006;112:253–260.
9. O’Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss
visualized with FP-CIT SPECT in the differential diagnosis of
dementia with Lewy bodies. Arch Neurol 2004;61:919–925.
10. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies:
a comparison of clinical diagnosis, FP-CIT single photon emission
computed tomography imaging and autopsy. J Neurol Neurosurg
Psychiatry 2007;78:1176–1181.
11. Nicastro N, Garibotto V, Allali G, Assal F, Burkhard PR. Added
value of combined semi-quantitative and visual [123I]FP-CIT
SPECT analyses for the diagnosis of dementia with Lewy bodies.
Clin Nucl Med 2017;42:e96–e102.
12. Nobili F, Arbizu J, Bouwman F, et al. European Association of
Nuclear Medicine and European Academy of Neurology recommen-
dations for the use of brain (18) F-fluorodeoxyglucose positron
emission tomography in neurodegenerative cognitive impairment
and dementia: Delphi consensus. Eur J Neurol 2018;25:1201–1217.
13. Morbelli S, Perneczky R, Drzezga A, et al. Metabolic networks
underlying cognitive reserve in prodromal Alzheimer disease: a
European Alzheimer disease consortium project. J Nucl Med 2013;
54:894–902.
14. Caminiti SP, Tettamanti M, Sala A, et al. Metabolic connectomics
targeting brain pathology in dementia with Lewy bodies. J Cereb
Blood Flow Metab 2017;37:1311–1325.
15. Galvin JE, Price JL, Yan Z, Morris JC, Sheline YI. Resting bold
fMRI differentiates dementia with Lewy bodies vs Alzheimer disease.
Neurology 2011;76:1797–1803.
16. Kenny ER, Blamire AM, Firbank MJ, O’Brien JT. Functional con-
nectivity in cortical regions in dementia with Lewy bodies and
Alzheimer’s disease. Brain 2012;135(Pt 2):569–581.
17. Peraza LR, Kaiser M, Firbank M, et al. fMRI resting state networks
and their association with cognitive fluctuations in dementia with
Lewy bodies. Neuroimage Clin 2014;4:558–565.
18. Peraza LR, Colloby SJ, Deboys L, O’Brien JT, Kaiser M, Taylor JP.
Regional functional synchronizations in dementia with Lewy bodies
and Alzheimer’s disease. Int Psychogeriatr 2016;28:1143–1151.
19. Schumacher J, Peraza LR, Firbank M, et al. Functional connectivity
in dementia with Lewy bodies: a within- and between-network anal-
ysis. Hum Brain Mapp 2018;39:1118–1129.
20. Ko JH, Lee CS, Eidelberg D. Metabolic network expression in par-
kinsonism: clinical and dopaminergic correlations. J Cereb Blood
Flow Metab 2017;37:683–693.
21. Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights
and clinical applications in Parkinson’s disease. Lancet Neurol
2018;17:629–640.
22. Niethammer M, Tang CC, Ma Y, et al. Parkinson’s disease cognitive
network correlates with caudate dopamine. Neuroimage 2013;78:
204–209.
604 Movement Disorders, Vol. 35, No. 4, 2020
H U B E R E T A L
23. Massa F, Arnaldi D, De Cesari F, et al. Neuroimaging findings and
clinical trajectories of Lewy body disease in patients with MCI. Neu-
robiol Aging 2019;76:9–17.
24. Biundo R, Weis L, Bostantjopoulou S, et al. MMSE and MoCA in
Parkinson’s disease and dementia with Lewy bodies: a multicenter
1-year follow-up study. J Neural Transm (Vienna) 2016;123:
431–438.
25. Morbelli S, Chincarini A, Brendel M, et al. Metabolic patterns
across core features in dementia with Lewy bodies. Ann Neurol
2019;85:715–725.
26. Albert NL, Unterrainer M, Diemling M, et al. Implementation of the
European multicentre database of healthy controls for [(123)I]FP-
CIT SPECT increases diagnostic accuracy in patients with clinically
uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging
2016;43:1315–1322.
27. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maxi-
mum probability atlas of the human brain, with particular reference
to the temporal lobe. Hum Brain Mapp 2003;19:224–247.
28. Yakushev I, Hammers A, Fellgiebel A, et al. SPM-based count nor-
malization provides excellent discrimination of mild Alzheimer’s dis-
ease and amnestic mild cognitive impairment from healthy aging.
Neuroimage 2009;44:43–50.
29. Brendel M, Kleinberger G, Probst F, et al. Increase of TREM2 during
aging of an Alzheimer’s disease mouse model is paralleled by micro-
glial activation and amyloidosis. Front Aging Neurosci 2017;9:8.
30. Horwitz B, Duara R, Rapoport SI. Intercorrelations of glucose meta-
bolic rates between brain regions: application to healthy males in a
state of reduced sensory input. J Cereb Blood Flow Metab 1984;4:
484–499.
31. Burkhardt JM, Jin X, Costa RM. Dissociable effects of dopamine on
neuronal firing rate and synchrony in the dorsal striatum. Front
Integr Neurosci 2009;3:28.
32. Plenz D, Kital ST. A basal ganglia pacemaker formed by the sub-
thalamic nucleus and external globus pallidus. Nature 1999;400:
677–682.
33. Chiba Y, Fujishiro H, Iseki E, Kasanuki K, Sato K. The cingulate
island sign on FDG-PET vs. IMP-SPECT to assess mild cognitive
impairment in Alzheimer’s disease vs. dementia with Lewy bodies.
J Neuroimaging 2019;29:712–720.
34. Celone KA, Calhoun VD, Dickerson BC, et al. Alterations in memory
networks in mild cognitive impairment and Alzheimer’s disease: an
independent component analysis. J Neurosci 2006;26:10222–10231.
35. Borghammer P, Cumming P, Aanerud J, Gjedde A. Artefactual
subcortical hyperperfusion in PET studies normalized to global
mean: lessons from Parkinson’s disease. Neuroimage 2009;45:
249–257.
36. Borghammer P, Jonsdottir KY, Cumming P, et al. Normalization in
PET group comparison studies—the importance of a valid reference
region. Neuroimage 2008;40:529–540.
37. Borghammer P, Chakravarty M, Jonsdottir KY, et al. Cortical
hypometabolism and hypoperfusion in Parkinson’s disease is exten-
sive: probably even at early disease stages. Brain Struct Funct 2010;
214:303–317.
38. Ma Y, Tang C, Moeller JR, Eidelberg D. Abnormal regional brain
function in Parkinson’s disease: truth or fiction? NeuroImage 2009;
45:260–266.
39. Lozza C, Marie RM, Baron JC. The metabolic substrates of
bradykinesia and tremor in uncomplicated Parkinson’s disease.
NeuroImage 2002;17:688–699.
40. Gardner RC, Boxer AL, Trujillo A, et al. Intrinsic connectivity net-
work disruption in progressive supranuclear palsy. Ann Neurol
2013;73:603–616.
41. Morbelli S, Drzezga A, Perneczky R, et al. Resting metabolic con-
nectivity in prodromal Alzheimer’s disease. A European Alzheimer
Disease Consortium (EADC) project. Neurobiol Aging 2012;33:
2533–2550.
Supporting Data
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site.
Movement Disorders, Vol. 35, No. 4, 2020 605
M E T A B O L I S M A N D D O P A M I N E R G I C L O S S I N D E M E N T I A W I T H L E W Y B O D I E S
